Skip to main content
SLS logo

SELLAS Life Sciences Group, Inc.

SLSNASDAQHealthcareBiotechnology

$9.98Today:- (-)1Y +429.91%

As of Oct 16, 2026 close

Market cap
$2.15B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.39$15.88
Volume (live)
-
Avg. volume (3M)
6.07M

SELLAS Life Sciences Group (SLS) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), SELLAS Life Sciences Group posted a net loss of $26.86M, compared with a net loss of $30.88M a year earlier.

SELLAS Life Sciences Group Income Statement Analysis

Values in millions USD

Scroll to see more
SELLAS Life Sciences Group, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue0.000.000.001.007.601.900.000.000.00
Cost of Revenue0.000.000.000.100.200.000.000.000.00
Gross Profit0.000.000.000.907.401.900.000.000.00
Operating Expenses
Research & Development16.0219.1024.0120.2715.679.2810.1218.326.07
Selling, General & Administrative11.1512.4213.8612.5811.329.609.9212.7715.09
Operating Expenses28.2731.5137.8732.8532.6918.8820.0431.5921.16
Operating Income-28.27-31.51-37.87-31.95-25.29-16.98-20.04-31.59-15.71
Other Income/Expense
Interest Income1.410.630.530.320.010.030.120.000.00
Interest Expense0.000.000.000.000.000.000.120.270.46
Other Income/Expense1.410.630.53-9.674.360.210.672.54-7.79
Income
Income Before Tax-26.86-30.88-37.34-41.30-20.94-16.77-19.37-29.05-23.50
Income Tax Expense0.000.000.000.00-0.24-0.02-0.08-1.380.25
Net Income-26.86-30.88-37.34-41.30-20.70-16.76-19.29-27.67-23.75
Net Income - Continuous Operations-26.86-30.88-37.34-41.30-20.70-16.76-19.29-27.67-23.75
Net Income - Discontinued Operations---------
EBITDA-28.27-31.51-37.87-31.95-25.29-16.400.000.00-23.04
EBIT-27.17-31.51-37.87-31.95-19.59-16.98---
Depreciation & Amortization0.0031.5137.870.461.270.3817.2122.040.00
Earnings Per Share
Basic EPS--1.00-1.00-2.00-1.00-2.00-11.00-158.00-522.00
Diluted EPS---1.00-2.00-1.00-2.00-11.00-158.00-522.00
Basic Shares Outstanding109.0561.2027.7819.4015.487.941.770.180.05
Diluted Shares Outstanding109.0561.2027.7819.4015.487.982.560.260.05

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About SELLAS Life Sciences Group Financial Statements

Is SELLAS Life Sciences Group profitable?

No. SELLAS Life Sciences Group reported a net loss of $26.86M in fiscal 2025. In fiscal 2024 it lost $30.88M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition